Page last updated: 2024-08-02 09:02:40
omacor
Description
Omacor: a drug containing the n-3 fatty acids that corrects plasma lipid; antiarrhthymic [MeSH]
Cross-References
Synonyms (15)
| Synonym |
|---|
| omacor |
| coromega |
| lovaza |
| omega-3-acid ethyl ester |
| icosapent (epa ethyl ester) |
| CHEMBL1200711 |
| doconexent (dha ethyl ester) |
| tak-085 |
| k-85 |
| 4,7,10,13,16,19-docosahexaenoic acid, ethyl ester, (4z,7z,10z,13z,16z,19z)-, mixt. with (5z,8z,11z,14z,17z)-ethyl 5,8,11,14,17-eicosapentaenoate |
| zodin |
| lotriga |
| 861006-80-6 |
| ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate compound with ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate (1:1) |
| ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate |
Research
Studies (108)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (34.26) | 29.6817 |
| 2010's | 71 (65.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 61 (53.04%) | 5.53% |
| Reviews | 13 (11.30%) | 6.00% |
| Case Studies | 3 (2.61%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 38 (33.04%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naphthalene | | naphthalenes;
ortho-fused bicyclic arene | apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| palmitic acid | | long-chain fatty acid;
straight-chain saturated fatty acid | algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2009 | 2016 | 10.2 | low | 5 | 0 | 0 | 1 | 4 | 0 |
| eicosapentaenoic acid ethyl ester | | | | 2010 | 2016 | 11.2 | low | 1 | 0 | 0 | 2 | 6 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| desoxycorticosterone | | 20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 2002 | 2014 | 15.0 | low | 3 | 0 | 0 | 3 | 1 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2001 | 2011 | 18.8 | low | 3 | 0 | 0 | 3 | 1 | 0 |
| raloxifene hydrochloride | | hydrochloride | bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2012 | 2017 | 9.0 | low | 3 | 0 | 0 | 0 | 3 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2002 | 2017 | 13.4 | low | 3 | 0 | 0 | 3 | 2 | 0 |
| ibandronic acid | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triazoles | | 1,2,3-triazole | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fibrinogen | | iditol | fungal metabolite | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| nepafenac | | monocarboxylic acid amide | cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| campesterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C28-steroid;
phytosterols | mouse metabolite | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| ramelteon | | indanes | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deferasirox | | benzoic acids;
monocarboxylic acid;
phenols;
triazoles | iron chelator | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lanosterol | | 14alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid | bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| arachidonic acid | | icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid | Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite | 2006 | 2015 | 13.2 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| palmitoleic acid | | hexadec-9-enoic acid | algal metabolite;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
human blood serum metabolite | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2012 | 2017 | 9.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2000 | 2019 | 12.7 | high | 58 | 0 | 1 | 39 | 64 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2004 | 2015 | 14.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| D-fructopyranose | | cyclic hemiketal;
D-fructose;
fructopyranose | sweetening agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 2016 | 2016 | 8.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| alpha-linolenic acid | | linolenic acid;
omega-3 fatty acid | micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2004 | 2015 | 14.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| phosphorus | | monoatomic phosphorus;
nonmetal atom;
pnictogen | macronutrient | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| pregabalin | | gamma-amino acid | anticonvulsant;
calcium channel blocker | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| 4,7,10,13,16,19-docosahexaenoic acid ethyl ester | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rosiglitazone-metformin combination | | | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| phytosterols | | | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| ubiquinone | | | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| cardiovascular agents | | | | 2002 | 2011 | 17.7 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| interleukin-8 | | | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| minocycline | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tigecycline | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| insulin glargine | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acute Confusional Senile Dementia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Disease | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Acute Edematous Pancreatitis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adverse Drug Event | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Aging | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Airflow Obstruction, Chronic | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Albuminuria | 0 | | 2010 | 2017 | 10.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Alloxan Diabetes | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alzheimer Disease | 1 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angina Pectoris, Stable | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Angina, Stable | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Anxiety | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Apolipoprotein B-100, Familial Defective | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmia | 0 | | 2009 | 2011 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Arrhythmias, Cardiac | 0 | | 2009 | 2011 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Arterial Diseases, Carotid | 0 | | 2010 | 2016 | 11.8 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| Arteriosclerosis, Coronary | 0 | | 2011 | 2017 | 10.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Asthma | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Asthma, Bronchial | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atherogenesis | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atherosclerosis | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atrial Fibrillation | 1 | | 2009 | 2012 | 13.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| Auricular Fibrillation | 0 | | 2009 | 2012 | 13.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| Behavior Disorders | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Neoplasms | 0 | | 2016 | 2016 | 8.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Berger Disease | 0 | | 2001 | 2015 | 18.0 | low | 5 | 0 | 0 | 5 | 1 | 0 |
| Blood Clot | 0 | | 2006 | 2016 | 12.5 | low | 4 | 0 | 0 | 2 | 2 | 0 |
| Blood Pressure, High | 0 | | 2006 | 2017 | 12.2 | low | 4 | 0 | 0 | 2 | 3 | 0 |
| Body Weight | 0 | | 2006 | 2012 | 15.0 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Breast Cancer | 0 | | 2012 | 2019 | 8.3 | low | 5 | 0 | 0 | 0 | 6 | 0 |
| Breast Neoplasms | 1 | | 2012 | 2019 | 8.3 | low | 5 | 0 | 0 | 0 | 6 | 0 |
| Cancer of Prostate | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carbohydrate Inducible Hyperlipemia | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cardiac Arrest, Sudden | 0 | | 2003 | 2012 | 18.2 | low | 2 | 0 | 0 | 4 | 1 | 0 |
| Cardiac Failure | 0 | | 2009 | 2012 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Cardiometabolic Syndrome | 0 | | 2010 | 2018 | 9.8 | low | 1 | 0 | 0 | 1 | 4 | 0 |
| Cardiovascular Diseases | 1 | | 2006 | 2016 | 12.4 | low | 6 | 0 | 0 | 4 | 6 | 0 |
| Cardiovascular Stroke | 0 | | 2002 | 2009 | 18.1 | low | 4 | 0 | 0 | 10 | 0 | 0 |
| Carditis | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Carotid Artery Diseases | 0 | | 2010 | 2016 | 11.8 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| Central Hypothyroidism | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Kidney Diseases | 0 | | 2015 | 2016 | 8.3 | low | 3 | 0 | 0 | 0 | 3 | 0 |
| Chronic Kidney Failure | 0 | | 2006 | 2015 | 12.6 | low | 5 | 0 | 0 | 2 | 3 | 0 |
| Chronic Lung Injury | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cirrhosis, Liver | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cognition Disorders | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complication, Postoperative | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Complications, Pregnancy | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Condition, Preneoplastic | 0 | | 2015 | 2015 | 9.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Coronary Artery Disease | 0 | | 2011 | 2017 | 10.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Coronary Disease | 0 | | 2001 | 2016 | 16.2 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| Coronary Heart Disease | 0 | | 2001 | 2016 | 16.2 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| Death, Sudden, Cardiac | 0 | | 2003 | 2012 | 18.2 | low | 2 | 0 | 0 | 4 | 1 | 0 |
| Depression | 0 | | 2006 | 2013 | 14.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| Diabetes Mellitus, Adult-Onset | 0 | | 2006 | 2019 | 11.5 | low | 5 | 0 | 0 | 4 | 4 | 0 |
| Diabetes Mellitus, Type 2 | 1 | | 2006 | 2019 | 11.5 | low | 5 | 0 | 0 | 4 | 4 | 0 |
| Diabetic Glomerulosclerosis | 0 | | 2010 | 2017 | 10.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Diabetic Nephropathies | 0 | | 2010 | 2017 | 10.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Disease Exacerbation | 0 | | 2006 | 2017 | 10.2 | low | 4 | 0 | 0 | 1 | 3 | 0 |
| Disease Models, Animal | 0 | | 2012 | 2018 | 9.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dyslipidemia | 0 | | 2007 | 2016 | 12.2 | low | 3 | 0 | 0 | 1 | 4 | 0 |
| Dyslipidemias | 0 | | 2007 | 2016 | 12.2 | low | 3 | 0 | 0 | 1 | 4 | 0 |
| Dyspepsia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Electrocardiogram QT Prolonged | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Elevated Cholesterol | 0 | | 2002 | 2017 | 13.6 | low | 2 | 0 | 0 | 4 | 3 | 0 |
| Endotoxemia | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Experimental Lung Inflammation | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Familial Combined Hyperlipidemia | 0 | | 2000 | 2009 | 19.5 | low | 2 | 0 | 1 | 1 | 0 | 0 |
| Fatty Liver | 1 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Fatty Liver, Nonalcoholic | 0 | | 2014 | 2016 | 8.8 | low | 4 | 0 | 0 | 0 | 4 | 0 |
| Glomerulonephritis, IGA | 1 | | 2001 | 2015 | 18.0 | low | 5 | 0 | 0 | 5 | 1 | 0 |
| Graft Occlusion, Vascular | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Heart Failure | 1 | | 2009 | 2012 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| HIV Coinfection | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| HIV Infections | 1 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Hypercholesterolemia | 1 | | 2002 | 2017 | 13.6 | low | 2 | 0 | 0 | 4 | 3 | 0 |
| Hyperlipemia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperlipidemia, Familial Combined | 1 | | 2000 | 2009 | 19.5 | low | 2 | 0 | 1 | 1 | 0 | 0 |
| Hyperlipidemias | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperlipoproteinemia Type II | 1 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hyperlipoproteinemia Type IV | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Hyperplasia | 0 | | 2015 | 2015 | 9.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Hypertension | 1 | | 2006 | 2017 | 12.2 | low | 4 | 0 | 0 | 2 | 3 | 0 |
| Hypertriglyceridemia | 1 | | 2001 | 2018 | 13.7 | low | 8 | 0 | 0 | 16 | 13 | 0 |
| Hypothyroidism | 1 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Indigestion | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Inflammation | 1 | | 2010 | 2014 | 12.2 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| Innate Inflammatory Response | 0 | | 2010 | 2014 | 12.2 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| Insulin Resistance | 1 | | 2013 | 2016 | 10.0 | low | 3 | 0 | 0 | 0 | 4 | 0 |
| Insulin Sensitivity | 0 | | 2013 | 2016 | 10.0 | low | 3 | 0 | 0 | 0 | 4 | 0 |
| Intermittent Claudication | 1 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Kidney Failure, Chronic | 0 | | 2006 | 2015 | 12.6 | low | 5 | 0 | 0 | 2 | 3 | 0 |
| Liver Cirrhosis | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Liver Steatosis | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Long QT Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Mental Disorders | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Metabolic Syndrome | 1 | | 2010 | 2018 | 9.8 | low | 1 | 0 | 0 | 1 | 4 | 0 |
| Myocardial Infarction | 1 | | 2002 | 2009 | 18.1 | low | 4 | 0 | 0 | 10 | 0 | 0 |
| Myocarditis | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Neoplasms | 0 | | 2016 | 2016 | 8.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Nephrosis | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Non-alcoholic Fatty Liver Disease | 1 | | 2014 | 2016 | 8.8 | low | 4 | 0 | 0 | 0 | 4 | 0 |
| Obesity | 0 | | 2013 | 2019 | 8.2 | low | 4 | 0 | 0 | 0 | 5 | 0 |
| Pancreatitis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Peripheral Arterial Disease | 1 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Peripheral Arterial Diseases | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Pneumonia | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Postoperative Complications | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Precancerous Conditions | 0 | | 2015 | 2015 | 9.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Pregnancy | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Prostatic Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Proteinuria | 0 | | 2004 | 2015 | 14.8 | low | 4 | 0 | 0 | 2 | 2 | 0 |
| Pulmonary Disease, Chronic Obstructive | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Recrudescence | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Renal Insufficiency, Chronic | 1 | | 2015 | 2016 | 8.3 | low | 3 | 0 | 0 | 0 | 3 | 0 |
| Rupture, Spontaneous | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Thrombosis | 0 | | 2006 | 2016 | 12.5 | low | 4 | 0 | 0 | 2 | 2 | 0 |
| Vascular Calcification | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Weight Loss | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Weight Reduction | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:5, 2010
Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women.Journal of proteome research, , 09-06, Volume: 18, Issue:9, 2019
Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women.European journal of clinical nutrition, , Volume: 71, Issue:6, 2017
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.), , Volume: 9, Issue:4, 2016
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial.European journal of clinical nutrition, , Volume: 66, Issue:8, 2012
Breast Cancer Genetic and Molecular Subtype Impacts Response to Omega-3 Fatty Acid Ethyl Esters.Nutrition and cancer, , Volume: 68, Issue:6
Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL).Contemporary clinical trials, , Volume: 47, 2016
Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy.Nutrition, metabolism, and cardiovascular diseases : NMCD, , Volume: 26, Issue:12, 2016
Update on the Vitamin D and OmegA-3 trial (VITAL).The Journal of steroid biochemistry and molecular biology, , Volume: 155, Issue:Pt B, 2016
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.The British journal of nutrition, , Volume: 107, Issue:6, 2012
Does coconut oil improve cholesterol by raising good cholesterol, or should I use fish oil?Mayo Clinic health letter (English ed.), , Volume: 30, Issue:8, 2012
Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients.Nutrition research (New York, N.Y.), , Volume: 32, Issue:7, 2012
Alpha-linolenic acid: is it essential to cardiovascular health?Current atherosclerosis reports, , Volume: 12, Issue:6, 2010
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Fish oil composition of Omacor and the GISSI trial.The American journal of cardiology, , May-15, Volume: 99, Issue:10, 2007
[Start of insulin therapy. How to ensure patient compliance?].MMW Fortschritte der Medizin, , Aug-31, Volume: 148, Issue:35-36, 2006
Using omega-3 fatty acids in the practice of clinical lipidology.Journal of clinical lipidology, , Volume: 5, Issue:6
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.Atherosclerosis, , Volume: 246, 2016
Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy.Marine drugs, , Sep-20, Volume: 11, Issue:9, 2013
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.Cardiology, , Volume: 118, Issue:3, 2011
Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.American journal of therapeutics, , Volume: 21, Issue:1
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 30, Issue:8, 2016
[Big gaps in coronary heart disease prevention. Statins are not enough in dyslipidemia].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.The Medical letter on drugs and therapeutics, , Nov-07, Volume: 47, Issue:1221, 2005
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.Heart (British Cardiac Society), , Volume: 85, Issue:5, 2001
Familial hypertriglyceridaemia and type 2 diabetes in pregnancy: prevention of acute pancreatitis with diet control and omega-3 fatty acids.BMJ case reports, , May-19, Volume: 12, Issue:5, 2019
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Impact of sex on the heart's metabolic and functional responses to diabetic therapies.American journal of physiology. Heart and circulatory physiology, , Dec-01, Volume: 305, Issue:11, 2013
Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:5, 2010
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.Atherosclerosis, , Volume: 213, Issue:2, 2010
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.Cardiovascular diabetology, , Jan-08, Volume: 8, 2009
[Start of insulin therapy. How to ensure patient compliance?].MMW Fortschritte der Medizin, , Aug-31, Volume: 148, Issue:35-36, 2006
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:5, 2010
Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 66, Issue:5, 2015
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:6, 2006
Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 87, Issue:2, 2004
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].BMC nephrology, , Mar-25, Volume: 5, 2004
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:4, 2001
Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".Canadian journal of physiology and pharmacology, , Volume: 90, Issue:1, 2012
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.American journal of therapeutics, , Volume: 21, Issue:1
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-LeprBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 85, 2017
Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 27, Issue:3, 2015
Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.Journal of cardiovascular pharmacology, , Volume: 57, Issue:4, 2011
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Mayo Clinic proceedings, , Volume: 85, Issue:2, 2010
[It can't be more compatible. Omega-3 fatty acids in addition to statin provide optimal lipid management].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
[Big gaps in coronary heart disease prevention. Statins are not enough in dyslipidemia].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.Minerva medica, , Volume: 93, Issue:5, 2002
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.Postgraduate medicine, , Volume: 127, Issue:8, 2015
Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".Canadian journal of physiology and pharmacology, , Volume: 90, Issue:1, 2012
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.Cardiovascular diabetology, , Jan-08, Volume: 8, 2009
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:6, 2006
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers.Molecular nutrition & food research, , Volume: 58, Issue:3, 2014
Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy.Marine drugs, , Sep-20, Volume: 11, Issue:9, 2013
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.Diabetes, obesity & metabolism, , Volume: 16, Issue:6, 2014
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Future cardiology, , Volume: 9, Issue:2, 2013
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes, , Volume: 62, Issue:5, 2013
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
n-3 polyunsaturated fatty acids and adiponectin in patients with end-stage renal disease.Clinical nephrology, , Volume: 83, Issue:5, 2015
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.The British journal of nutrition, , Volume: 107, Issue:6, 2012
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.BMC nephrology, , Jan-21, Volume: 10, 2009
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.Drugs, , May-29, Volume: 69, Issue:8, 2009
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients post-myocardial infarction.International journal of cardiology, , Jan-31, Volume: 115, Issue:1, 2007
Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients.International journal of clinical practice, , Volume: 60, Issue:8, 2006
Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.Thrombosis research, , Volume: 118, Issue:3, 2006
Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
[More safety after myocardial infarct].Krankenpflege Journal, , Volume: 43, Issue:7-10, 2005
[Additional omega-3-fatty acids. Infarct mortality gets reduced].MMW Fortschritte der Medizin, , Mar-06, Volume: 145, Issue:10, 2003
Further reduction in mortality following myocardial infarction.Hospital medicine (London, England : 1998), , Volume: 63, Issue:10, 2002
Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Indian heart journal, , Volume: 64, Issue:5
Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women.Journal of proteome research, , 09-06, Volume: 18, Issue:9, 2019
Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women.European journal of clinical nutrition, , Volume: 71, Issue:6, 2017
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.), , Volume: 9, Issue:4, 2016
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.Diabetes, obesity & metabolism, , Volume: 16, Issue:6, 2014
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes, , Volume: 62, Issue:5, 2013
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 66, Issue:5, 2015
The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.Clinical nephrology, , Volume: 77, Issue:6, 2012
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].BMC nephrology, , Mar-25, Volume: 5, 2004
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.Nephrology (Carlton, Vic.), , Volume: 21, Issue:3, 2016
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.BMC nephrology, , Jan-21, Volume: 10, 2009
Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.Thrombosis research, , Volume: 118, Issue:3, 2006
Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.Clinical therapeutics, , Volume: 40, Issue:1, 2018
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesClinical therapeutics, , Volume: 39, Issue:3, 2017
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.Lipids in health and disease, , Jul-22, Volume: 15, Issue:1, 2016
Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 27, Issue:3, 2015
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.Postgraduate medicine, , Volume: 127, Issue:8, 2015
Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.Cardiovascular therapeutics, , Volume: 33, Issue:6, 2015
Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.Postgraduate medicine, , Volume: 126, Issue:7, 2014
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Future cardiology, , Volume: 9, Issue:2, 2013
Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia.Psychosomatic medicine, , Volume: 75, Issue:4, 2013
Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.The Medical letter on drugs and therapeutics, , Apr-29, Volume: 55, Issue:1415, 2013
Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy.Lipids in health and disease, , Oct-30, Volume: 11, 2012
Fish oil supplements.The Medical letter on drugs and therapeutics, , Oct-15, Volume: 54, Issue:1401, 2012
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.Cardiology, , Volume: 118, Issue:3, 2011
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Mayo Clinic proceedings, , Volume: 85, Issue:2, 2010
Triglycerides & omega-3s. Prescription omega-3 fatty acids are now among the hypertriglyceridemia therapies.Advance for NPs & PAs, , Volume: 1, Issue:4, 2010
The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet.Lipids, , Volume: 44, Issue:9, 2009
Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.Postgraduate medicine, , Volume: 121, Issue:4, 2009
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.Drugs, , May-29, Volume: 69, Issue:8, 2009
[Big gaps in coronary heart disease prevention. Statins are not enough in dyslipidemia].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
[It can't be more compatible. Omega-3 fatty acids in addition to statin provide optimal lipid management].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.Current medical research and opinion, , Volume: 23, Issue:5, 2007
Omacor effects on serum lipids and clinical outcome.The American journal of cardiology, , Jan-01, Volume: 99, Issue:1, 2007
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.Clinical therapeutics, , Volume: 29, Issue:7, 2007
Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.The American journal of cardiology, , Aug-21, Volume: 98, Issue:4A, 2006
[More safety after myocardial infarct].Krankenpflege Journal, , Volume: 43, Issue:7-10, 2005
Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.The Medical letter on drugs and therapeutics, , Nov-07, Volume: 47, Issue:1221, 2005
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.Minerva medica, , Volume: 93, Issue:5, 2002
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.Heart (British Cardiac Society), , Volume: 85, Issue:5, 2001
Using omega-3 fatty acids in the practice of clinical lipidology.Journal of clinical lipidology, , Volume: 5, Issue:6
Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Indian heart journal, , Volume: 64, Issue:5
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.Journal of clinical lipidology, , Volume: 6, Issue:6
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.Journal of clinical lipidology, , Volume: 7, Issue:6
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.The British journal of nutrition, , Volume: 107, Issue:6, 2012
Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
[More safety after myocardial infarct].Krankenpflege Journal, , Volume: 43, Issue:7-10, 2005
[Additional omega-3-fatty acids. Infarct mortality gets reduced].MMW Fortschritte der Medizin, , Mar-06, Volume: 145, Issue:10, 2003
[Sudden cardiac death. Targets every 2nd person without warning].MMW Fortschritte der Medizin, , Jan-30, Volume: 145, Issue:5, 2003
Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Indian heart journal, , Volume: 64, Issue:5
Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.Marine drugs, , May-24, Volume: 16, Issue:6, 2018
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-LeprBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 85, 2017
Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.Neurochemical research, , Volume: 38, Issue:10, 2013
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes, , Volume: 62, Issue:5, 2013
Triglycerides & omega-3s. Prescription omega-3 fatty acids are now among the hypertriglyceridemia therapies.Advance for NPs & PAs, , Volume: 1, Issue:4, 2010
Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.Current vascular pharmacology, , Volume: 14, Issue:5, 2016
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.Diabetes, obesity & metabolism, , Volume: 16, Issue:6, 2014
Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability.European journal of clinical nutrition, , Volume: 65, Issue:1, 2011
When to take statins; Lovaza versus OTC fish oil supplements.JAAPA : official journal of the American Academy of Physician Assistants, , Volume: 24, Issue:5, 2011
Fish oil composition of Omacor and the GISSI trial.The American journal of cardiology, , May-15, Volume: 99, Issue:10, 2007
New drugs: pregabalin and omega-3-acid ethyl esters.Journal of the American Pharmacists Association : JAPhA, , Volume: 45, Issue:6
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.Nephrology (Carlton, Vic.), , Volume: 21, Issue:3, 2016
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease.Nutrients, , Mar-19, Volume: 8, Issue:3, 2016
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.Atherosclerosis, , Volume: 246, 2016
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.Journal of hepatology, , Volume: 63, Issue:6, 2015
Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].Contemporary clinical trials, , Volume: 37, Issue:2, 2014
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.Atherosclerosis, , Volume: 246, 2016
Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung fuContemporary clinical trials, , Volume: 47, 2016
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.Marine drugs, , May-24, Volume: 16, Issue:6, 2018
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-LeprBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 85, 2017
Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.Neurochemical research, , Volume: 38, Issue:10, 2013
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes, , Volume: 62, Issue:5, 2013
Triglycerides & omega-3s. Prescription omega-3 fatty acids are now among the hypertriglyceridemia therapies.Advance for NPs & PAs, , Volume: 1, Issue:4, 2010
Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.Current vascular pharmacology, , Volume: 14, Issue:5, 2016
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.Diabetes, obesity & metabolism, , Volume: 16, Issue:6, 2014
Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability.European journal of clinical nutrition, , Volume: 65, Issue:1, 2011
When to take statins; Lovaza versus OTC fish oil supplements.JAAPA : official journal of the American Academy of Physician Assistants, , Volume: 24, Issue:5, 2011
Fish oil composition of Omacor and the GISSI trial.The American journal of cardiology, , May-15, Volume: 99, Issue:10, 2007
New drugs: pregabalin and omega-3-acid ethyl esters.Journal of the American Pharmacists Association : JAPhA, , Volume: 45, Issue:6
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease.Nutrients, , Mar-19, Volume: 8, Issue:3, 2016
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.Nephrology (Carlton, Vic.), , Volume: 21, Issue:3, 2016
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.Atherosclerosis, , Volume: 246, 2016
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.Journal of hepatology, , Volume: 63, Issue:6, 2015
Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].Contemporary clinical trials, , Volume: 37, Issue:2, 2014
Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy.Lipids in health and disease, , Oct-30, Volume: 11, 2012
The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet.Lipids, , Volume: 44, Issue:9, 2009
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women.Journal of proteome research, , 09-06, Volume: 18, Issue:9, 2019
Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women.European journal of clinical nutrition, , Volume: 71, Issue:6, 2017
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.Cancer prevention research (Philadelphia, Pa.), , Volume: 9, Issue:4, 2016
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial.European journal of clinical nutrition, , Volume: 66, Issue:8, 2012
Breast Cancer Genetic and Molecular Subtype Impacts Response to Omega-3 Fatty Acid Ethyl Esters.Nutrition and cancer, , Volume: 68, Issue:6
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.Atherosclerosis, , Volume: 246, 2016
Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy.Marine drugs, , Sep-20, Volume: 11, Issue:9, 2013
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.Cardiology, , Volume: 118, Issue:3, 2011
Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.American journal of therapeutics, , Volume: 21, Issue:1
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 30, Issue:8, 2016
[Big gaps in coronary heart disease prevention. Statins are not enough in dyslipidemia].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.The Medical letter on drugs and therapeutics, , Nov-07, Volume: 47, Issue:1221, 2005
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.Heart (British Cardiac Society), , Volume: 85, Issue:5, 2001
Familial hypertriglyceridaemia and type 2 diabetes in pregnancy: prevention of acute pancreatitis with diet control and omega-3 fatty acids.BMJ case reports, , May-19, Volume: 12, Issue:5, 2019
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Impact of sex on the heart's metabolic and functional responses to diabetic therapies.American journal of physiology. Heart and circulatory physiology, , Dec-01, Volume: 305, Issue:11, 2013
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.Atherosclerosis, , Volume: 213, Issue:2, 2010
Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:5, 2010
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.Cardiovascular diabetology, , Jan-08, Volume: 8, 2009
[Start of insulin therapy. How to ensure patient compliance?].MMW Fortschritte der Medizin, , Aug-31, Volume: 148, Issue:35-36, 2006
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:5, 2010
Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 66, Issue:5, 2015
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:6, 2006
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].BMC nephrology, , Mar-25, Volume: 5, 2004
Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 87, Issue:2, 2004
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:4, 2001
Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".Canadian journal of physiology and pharmacology, , Volume: 90, Issue:1, 2012
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.American journal of therapeutics, , Volume: 21, Issue:1
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-LeprBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 85, 2017
Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 27, Issue:3, 2015
Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.Journal of cardiovascular pharmacology, , Volume: 57, Issue:4, 2011
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Mayo Clinic proceedings, , Volume: 85, Issue:2, 2010
[Big gaps in coronary heart disease prevention. Statins are not enough in dyslipidemia].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
[It can't be more compatible. Omega-3 fatty acids in addition to statin provide optimal lipid management].MMW Fortschritte der Medizin, , Nov-12, Volume: 151, Issue:46, 2009
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.Minerva medica, , Volume: 93, Issue:5, 2002
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association, , Jul-14, Volume: 6, Issue:7, 2017
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.Postgraduate medicine, , Volume: 127, Issue:8, 2015
Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".Canadian journal of physiology and pharmacology, , Volume: 90, Issue:1, 2012
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.Cardiovascular diabetology, , Jan-08, Volume: 8, 2009
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:6, 2006
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers.Molecular nutrition & food research, , Volume: 58, Issue:3, 2014
Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy.Marine drugs, , Sep-20, Volume: 11, Issue:9, 2013
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.Atherosclerosis, , Volume: 212, Issue:1, 2010
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.Diabetologia, , Volume: 59, Issue:7, 2016
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.Diabetes, obesity & metabolism, , Volume: 16, Issue:6, 2014
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes, , Volume: 62, Issue:5, 2013
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Future cardiology, , Volume: 9, Issue:2, 2013
n-3 polyunsaturated fatty acids and adiponectin in patients with end-stage renal disease.Clinical nephrology, , Volume: 83, Issue:5, 2015
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.The British journal of nutrition, , Volume: 107, Issue:6, 2012
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.BMC nephrology, , Jan-21, Volume: 10, 2009
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5, 2006
Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.Drugs, , May-29, Volume: 69, Issue:8, 2009
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.Advances in therapy, , Volume: 26, Issue:7, 2009
Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients post-myocardial infarction.International journal of cardiology, , Jan-31, Volume: 115, Issue:1, 2007
Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients.International journal of clinical practice, , Volume: 60, Issue:8, 2006
Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.Thrombosis research, , Volume: 118, Issue:3, 2006
Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
[More safety after myocardial infarct].Krankenpflege Journal, , Volume: 43, Issue:7-10, 2005
[Additional omega-3-fatty acids. Infarct mortality gets reduced].MMW Fortschritte der Medizin, , Mar-06, Volume: 145, Issue:10, 2003
Further reduction in mortality following myocardial infarction.Hospital medicine (London, England : 1998), , Volume: 63, Issue:10, 2002
Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Indian heart journal, , Volume: 64, Issue:5
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.Cancer prevention research (Philadelphia, Pa.), , Volume: 8, Issue:10, 2015
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.Nephrology (Carlton, Vic.), , Volume: 21, Issue:3, 2016
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.BMC nephrology, , Jun-27, Volume: 16, 2015
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.BMC nephrology, , Jan-21, Volume: 10, 2009
Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.Thrombosis research, , Volume: 118, Issue:3, 2006
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.The British journal of nutrition, , Volume: 107, Issue:6, 2012
Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study.Cardiovascular drugs and therapy, , Volume: 20, Issue:5, 2006
[More safety after myocardial infarct].Krankenpflege Journal, , Volume: 43, Issue:7-10, 2005
[Sudden cardiac death. Targets every 2nd person without warning].MMW Fortschritte der Medizin, , Jan-30, Volume: 145, Issue:5, 2003
[Additional omega-3-fatty acids. Infarct mortality gets reduced].MMW Fortschritte der Medizin, , Mar-06, Volume: 145, Issue:10, 2003
Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Indian heart journal, , Volume: 64, Issue:5
Safety/Toxicity (3)
| Article | Year |
|---|
Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Clinical therapeutics, , Volume: 40, Issue:1 | 2018 |
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
Journal of clinical lipidology, , Volume: 7, Issue:6 | |
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
American heart journal, , Volume: 158, Issue:2 | 2009 |
Long-term Use (1)
Bioavailability (5)
| Article | Year |
|---|
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Clinical therapeutics, , Volume: 39, Issue:3 | 2017 |
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Lipids in health and disease, , Jul-22, Volume: 15, Issue:1 | 2016 |
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Vascular health and risk management, , Volume: 9 | 2013 |
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
Future cardiology, , Volume: 9, Issue:2 | 2013 |
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Journal of clinical lipidology, , Volume: 6, Issue:6 | |
Dosage (9)
| Article | Year |
|---|
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Clinical therapeutics, , Volume: 39, Issue:3 | 2017 |
Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung fu
Contemporary clinical trials, , Volume: 47 | 2016 |
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Vascular health and risk management, , Volume: 9 | 2013 |
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Journal of clinical lipidology, , Volume: 6, Issue:6 | |
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
Biomedical chromatography : BMC, , Volume: 25, Issue:6 | 2011 |
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
Mayo Clinic proceedings, , Volume: 85, Issue:2 | 2010 |
Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Advances in therapy, , Volume: 26, Issue:7 | 2009 |
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:6 | 2006 |
Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Clinical journal of the American Society of Nephrology : CJASN, , Volume: 1, Issue:5 | 2006 |